Morgan Stanley Maintains Stevanato Group(STVN.US) With Hold Rating, Maintains Target Price $23
William Blair Maintains Stevanato Group(STVN.US) With Buy Rating
William Blair Remains a Buy on Stevanato Group (STVN)
Morgan Stanley Maintains Stevanato Group(STVN.US) With Hold Rating, Maintains Target Price $23
Morgan Stanley Sticks to Their Hold Rating for Stevanato Group (STVN)
BofA Securities Maintains Stevanato Group(STVN.US) With Buy Rating, Maintains Target Price $26
Morgan Stanley Maintains Stevanato Group(STVN.US) With Hold Rating, Maintains Target Price $23
UBS Maintains Stevanato Group(STVN.US) With Hold Rating, Cuts Target Price to $23.5
Stevanato Group Is Maintained at Neutral by UBS
Stevanato Group Analyst Ratings
Citi Maintains Stevanato Group(STVN.US) With Buy Rating, Maintains Target Price $28
William Blair Initiates Stevanato Group(STVN.US) With Buy Rating
Analysts Have Conflicting Sentiments on These Healthcare Companies: Fate Therapeutics (FATE) and Stevanato Group (STVN)
Morgan Stanley Maintains Stevanato Group(STVN.US) With Hold Rating, Maintains Target Price $23
Morgan Stanley Maintains Stevanato Group(STVN.US) With Hold Rating, Maintains Target Price $23
Analysts Conflicted on These Healthcare Names: Pharvaris (PHVS) and Stevanato Group (STVN)
Morgan Stanley Maintains Stevanato Group(STVN.US) With Hold Rating, Maintains Target Price $23
Morgan Stanley Reaffirms Their Hold Rating on Stevanato Group (STVN)
Stevanato Group Initiated at Outperform by Wolfe Research
BofA Securities Maintains Stevanato Group(STVN.US) With Buy Rating, Raises Target Price to $26